Neurocrine Biosciences
Neurology and Endocrinology Research and Therapy | Neurocrine Biosciences.
Launch date
Employees
Market cap
AUD18.9b
Enterprise valuation
AUD17.7b (Public information from Sep 2024)
Share price
$117.75 NBIX
San Diego California (HQ)
Financials
Estimates*
USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
---|---|---|---|---|---|---|---|
Revenues | 1.0b | 1.1b | 1.5b | 1.9b | 2.3b | 2.7b | 3.2b |
% growth | 33 % | 8 % | 31 % | 27 % | 24 % | 16 % | 18 % |
EBITDA | 328m | 208m | 249m | 416m | 630m | 849m | 1.2b |
% EBITDA margin | 31 % | 18 % | 17 % | 22 % | 27 % | 31 % | 37 % |
Profit | 407m | 89.6m | 155m | 250m | 455m | 706m | 967m |
% profit margin | 39 % | 8 % | 10 % | 13 % | 19 % | 26 % | 30 % |
EV / revenue | 8.1x | 6.8x | 7.0x | 6.0x | 4.7x | 3.7x | 2.9x |
EV / EBITDA | 25.9x | 37.1x | 41.6x | 27.4x | 17.3x | 11.9x | 7.8x |
R&D budget | 275m | 328m | 464m | 565m | - | - | - |
R&D % of revenue | 26 % | 29 % | 31 % | 30 % | - | - | - |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | N/A | IPO | |
$10.0m | Post IPO Equity | ||
Total Funding | - |
Recent News about Neurocrine Biosciences
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Neurocrine Biosciences
Editexited
ACQUISITION by Neurocrine Biosciences Aug 2022
exited